Bax inhibitor peptide V5

Bax inhibitor peptide V5 is a Bax-mediated apoptosis inhibitor, used for cancer treatment.

Signaling Pathways >> Apoptosis >> Bcl-2 Family

Peptides

Research Areas >> Cancer

Bax

Bax inhibitor peptide V5 (0-50 μM) reduces cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells. BIPV5 does not result in any significant effect on cell cycle arrest at the G2/M phase[1]. V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively[2].

V5 (100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation in mice model[2].

Cells (2.5×104 cells/mL) are grown in 96-well plates in a final volume of 100 μL/well. After 24 h, cells are incubated with small molecules or vehicle (DMSO) for 48-96 h prior to harvest. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole (MTT) reagent (0.5 mg/mL), is added to each well during the final 2 h, and absorbance is measured. Cell growth is calculated as the ratio of absorbance obtained upon compound treatment to that obtained with vehicle (DMSO) treatment.

[1]. Jo MJ, et al. Regulation of cancer cell death by a novel compound, C604, in a c-Myc-overexpressing cellular environment. Eur J Pharmacol. 2015 Dec 15;769:257-65.

[2]. Rivas-Carrillo JD, et al. Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice. Diabetes. 2007 May;56(5):1259-67. Epub 2007 Feb 7.

Venetoclax (ABT-199) | ABT-263 | S63845 | ABT-737 | Obatoclax Mesylate | A-1210477 | A-1155463 | WEHI-539 hydrochloride | A-1331852 | FX 1 | Gambogic Acid | TW-37 | UMI-77 | Acetate gossypol | HA14-1